The Inception Research Institute and Granata Bio, a biopharma company focused on women’s health and infertility, are partnering in the GRACE Study, a clinical trial evaluating a new human menopausal gonadotropin (hMG).
Human menopausal gonadotropins (hMGs) help the ovaries produce more eggs during an assisted reproductive technology (ART) cycle and have been used for over 50 years to treat infertility in the US and other countries around the world.
Granta Bio has developed GB-hMG, a potential fertility treatment that has not been approved by the FDA. The purpose of this trial is to evaluate the efficacy and safety of GB-hMG in women undergoing ART.
We are seeking women who are planning IVF at one of our participating fertility clinics.
Study participants must meet the following criteria:
Additional eligibility criteria apply.
Patients who wish to participate in the study will be asked to sign informed consent and undergo a formal screening assessment by the Research team at the clinic.
You will be randomly assigned (like the flip of a coin) to one of two groups: 1. GB-hMG (active drug) or 2. Placebo (inactive substance)
You will undergo one blinded IVF cycle which means neither you nor the study team will know which study treatment you are receiving
After Period 1, you have the option to undergo an open-label IVF cycle which means you will receive active GB-hMG
the study drug, study-related procedures, and study visits at no charge
If you’re interested in participating, please complete the form and a member of the research team will contact you to discuss the study details.